NervGen Pharma Corp. (NGEN.V)
| Previous Close | 2.7700 |
| Open | 2.7600 |
| Bid | 2.9400 x 0 |
| Ask | 2.9500 x 0 |
| Day's Range | 2.6700 - 2.8100 |
| 52 Week Range | 1.2600 - 3.3300 |
| Volume | |
| Avg. Volume | 78,988 |
| Market Cap | 115.377M |
| Beta (5Y Monthly) | 1.98 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.3440 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 6.00 |
- Newsfile
NervGen Pharma Corp. Closes Non-Brokered Private Placement
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATESVancouver, British Columbia--(Newsfile Corp. - November 29, 2021) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" the "Company"), a clinical stage biotech company dedicated to creating innovative solutions for the treatment of nervous system damage, is pleased to announce that it has closed a non-brokered private placement (the "Private Placement") of 892,721 units of the Company at a price of .
- Newsfile
NervGen Pharma Reports Third Quarter 2021 Results
Vancouver, British Columbia--(Newsfile Corp. - November 18, 2021) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, today reported its financial and operational results for the third quarter ended September 30, 2021."Most notably, we made important progress in our Phase 1 clinical trial with NVG-291 in the third quarter of 2021," stated Paul Bre
- Newsfile
NervGen Pharma Completes $9.2 Million Bought Deal Financing
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATESVancouver, British Columbia--(Newsfile Corp. - November 12, 2021) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to creating innovative treatments for nervous system damage, is pleased to announce the closing of its previously announced public offering (the "Offering") including the full exercise of the underwriters' over-allotment o
